Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
:CDXS
CDXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.56 - $6.08
Previous CloseN/A
Volume271.47K
Average Volume (3M)595.02K
Market Cap
$346.67M
Enterprise Value$172.94M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.19
Next Earnings
Feb 27, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding81,377,850
10 Day Avg. Volume453,927
30 Day Avg. Volume595,022
Standard Deviation0.24
R-Squared0.22
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.34
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.02
Enterprise Value/Ebitda-4.12
Forecast
1Y Price Target
$11.00Price Target Upside158.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Codexis News
PremiumCompany Announcements
Codexis Appoints Christos Richards to Board of Directors
PremiumCompany Announcements
Codexis Strengthens Board and Updates Bylaws
PremiumCompany Announcements
Codexis Reports Strong Q3 Revenue Growth
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCodexis extended their cash runway into 2027 with a $31M raise, which should increase confidence in the company's ability to reach cash flow positivity.
Product DevelopmentCodexis is now bringing some enzyme production in-house so they can scale rapidly to meet demand, which should be a meaningful tailwind to margins if it accelerates growth.
Strategic PartnershipsThe recent licensing of their genomics/life sciences enzyme portfolio to Alphazyme is an important point of execution that should now keep the focus on maximizing the commercial success of ECO Synthesis.
Bears Say
Customer Base DiversificationManagement highlighted progress in adding and diversifying to their Big 3 Pharma manufacturing customers.
Long-term OutlookExecuting on the right partnerships remains critical to the long-term outlook.
Product RevenueManagement expects Q2 Product revenues will be the lowest of the year, implying an anticipated increase in future quarters.
---
Ownership Overview
13.11% Insiders
19.07% Mutual Funds
9.95% Other Institutional Investors
47.81% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $2.56 and its highest was $6.08 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $346.67M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Feb 27, 2025 which is in 5 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Oct 31, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.239 by -$0.051.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.04.
How many shares outstanding does Codexis have?
Codexis has 81,377,850 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.239. Following the earnings report the stock price went up 11.465%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
---
Codexis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (158.22% Upside)
$11.00 (158.22% Upside)
Insider Transactions
Bought Shares
Worth $698.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.40%
12-Months-Change
Fundamentals
Return on Equity
-75.31%
Trailing 12-Months
Asset Growth
-4.06%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.
---
CDXS Company Deck
---
CDXS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Codexis demonstrated strong revenue growth and strategic leadership enhancements, with a clear path to profitability by 2026. However, challenges such as a decrease in R&D revenue and increased SG&A expenses were noted. Overall, the sentiment leans towards optimism with focus on future growth and profitability.Read More>---
CDXS Stock 12 Month Forecast
Average Price Target
$11.00
▲(158.22% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Denali Therapeutics
―
Best Analysts Covering CDXS
1 Year
1 Year Success Rate
12/23 ratings generated profit
1 Year Average Return
+5.82%
reiterated a buy rating 15 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +5.82% per trade.
---